Dos Santos F, Brin M, Tanner M, Galindo C, Schnall R
JMIR Hum Factors. 2025; 12:e59780.
PMID: 40019786
PMC: 11887583.
DOI: 10.2196/59780.
Merchant E, Solleveld P, Gibas K, Krakower D
PLoS One. 2024; 19(12):e0311591.
PMID: 39636888
PMC: 11620414.
DOI: 10.1371/journal.pone.0311591.
Denson D, Stanley A, Randall L, Tesfaye C, Glusberg D, Cardo J
J Homosex. 2024; 1-19.
PMID: 38989968
PMC: 11724005.
DOI: 10.1080/00918369.2024.2373803.
Moschese D, Lazzarin S, Colombo M, Caruso F, Giacomelli A, Antinori S
Viruses. 2024; 16(6).
PMID: 38932243
PMC: 11209220.
DOI: 10.3390/v16060951.
Horvath K, Helm J, Black A, Chase G, Ma J, Klaphake J
AIDS Behav. 2024; 28(8):2804-2820.
PMID: 38816592
DOI: 10.1007/s10461-024-04374-3.
Adapting mHealth Interventions (PrEPmate and DOT Diary) to Support PrEP Retention in Care and Adherence Among English and Spanish-Speaking Men Who Have Sex With Men and Transgender Women in the United States: Formative Work and Pilot Randomized Trial.
Liu A, Alleyne C, Doblecki-Lewis S, Koester K, Gonzalez R, Vinson J
JMIR Form Res. 2024; 8:e54073.
PMID: 38536232
PMC: 11007601.
DOI: 10.2196/54073.
Demographics, Trends, and Clinical Characteristics of HIV Pre-Exposure Prophylaxis Recipients and People Newly Diagnosed with HIV from Large Electronic Health Records in Florida.
Liu Y, Siddiqi K, Cho H, Park H, Prosperi M, Cook R
AIDS Patient Care STDS. 2024; 38(1):14-22.
PMID: 38227279
PMC: 10794838.
DOI: 10.1089/apc.2023.0220.
Optimizing HIV PrEP Persistence: Does Your Pharmacy Matter?.
Whelchel K, Zuckerman A, DeClercq J, Choi L, Kelly S
AIDS Behav. 2023; 27(11):3735-3744.
PMID: 37266824
DOI: 10.1007/s10461-023-04091-3.
Increasing Participation in a TelePrEP Program for Sexual and Gender Minority Adolescents and Young Adults in Louisiana: Protocol for an SMS Text Messaging-Based Chatbot.
Braddock W, Ocasio M, Comulada W, Mandani J, Fernandez M
JMIR Res Protoc. 2023; 12:e42983.
PMID: 37256669
PMC: 10267782.
DOI: 10.2196/42983.
Community pharmacists' acceptance of prescribing pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV).
Booker C, Murphy A, Isenor J, Ramsey T, Smith A, Bishop A
Can Pharm J (Ott). 2023; 156(3):137-149.
PMID: 37201164
PMC: 10186867.
DOI: 10.1177/17151635231152218.
Causal Effects of Stochastic PrEP Interventions on HIV Incidence Among Men Who Have Sex With Men.
Sewak A, Lodi S, Li X, Shu D, Wen L, Mayer K
Am J Epidemiol. 2023; 193(1):6-16.
PMID: 37073419
PMC: 10773485.
DOI: 10.1093/aje/kwad097.
Knowledge domain and emerging trends in HIV pre-exposure prophylaxis: A visualization analysis CiteSpace.
Chen X, Lai Y
Front Microbiol. 2023; 14:1099132.
PMID: 37007528
PMC: 10060873.
DOI: 10.3389/fmicb.2023.1099132.
SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders.
Ouyang J, Zaongo S, Harypursat V, Li X, Routy J, Chen Y
Front Public Health. 2022; 10:945448.
PMID: 36003629
PMC: 9393547.
DOI: 10.3389/fpubh.2022.945448.
Using the COM-B model to characterize the barriers and facilitators of pre-exposure prophylaxis (PrEP) uptake in men who have sex with men.
Madhani A, Finlay K
Br J Health Psychol. 2022; 27(4):1330-1353.
PMID: 35698439
PMC: 9796940.
DOI: 10.1111/bjhp.12605.
Why Do HIV Pre-Exposure Prophylaxis Users Discontinue Pre-Exposure Prophylaxis Care? A Mixed Methods Survey in a Pre-Exposure Prophylaxis Clinic in Belgium.
Vanbaelen T, Rotsaert A, Jacobs B, Florence E, Kenyon C, Vuylsteke B
AIDS Patient Care STDS. 2022; 36(4):159-167.
PMID: 35438524
PMC: 9057878.
DOI: 10.1089/apc.2021.0197.
Feasibility and Acceptability of Home-Collected Samples for Human Immunodeficiency Virus Preexposure Prophylaxis and Severe Acute Respiratory Syndrome Coronavirus 2 Laboratory Tests in San Francisco Primary Care Clinics.
Saberi P, Ming K, Shrestha I, Scott H, Thorson B, Liu A
Open Forum Infect Dis. 2022; 9(2):ofab657.
PMID: 35087913
PMC: 8789566.
DOI: 10.1093/ofid/ofab657.
Characterization of HIV Preexposure Prophylaxis Use Behaviors and HIV Incidence Among US Adults in an Integrated Health Care System.
Hojilla J, Hurley L, Marcus J, Silverberg M, Skarbinski J, Satre D
JAMA Netw Open. 2021; 4(8):e2122692.
PMID: 34436609
PMC: 8391097.
DOI: 10.1001/jamanetworkopen.2021.22692.
Primary Care Providers' Perspectives on Using Automated HIV Risk Prediction Models to Identify Potential Candidates for Pre-exposure Prophylaxis.
van den Berg P, Powell V, Wilson I, Klompas M, Mayer K, Krakower D
AIDS Behav. 2021; 25(11):3651-3657.
PMID: 33797668
PMC: 8631042.
DOI: 10.1007/s10461-021-03252-6.
Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.
Bekerman E, Cox S, Babusis D, Campigotto F, Das M, Barouch D
J Antimicrob Chemother. 2020; 76(3):692-698.
PMID: 33202006
PMC: 7879143.
DOI: 10.1093/jac/dkaa476.
Projected Impact of Concurrently Available Long-Acting Injectable and Daily-Oral Human Immunodeficiency Virus Preexposure Prophylaxis: A Mathematical Model.
Maloney K, Le Guillou A, Driggers R, Sarkar S, Anderson E, Malik A
J Infect Dis. 2020; 223(1):72-82.
PMID: 32882043
PMC: 7781468.
DOI: 10.1093/infdis/jiaa552.
